Drugs for Neglected Diseases Initiative (DNDi)


A collaborative, patients’ needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for neglected diseases recently announced the registration of fexinidazole –

an oral treatment for sleeping sickness or human African trypanosomiasis (HAT). HAT is endemic in 36 African countries and those affected by sleeping sickness are some of the most vulnerable and live in some of the most remote areas of the

Follow Our Journey